Exor put a number on its next big cheque, and the next day explained why it would not sign it yet

On 23 March 2026, Exor did something rare for an investment company: it gave a size to what it might buy next. After several disposals, the holding company expected to lift capital available for redeployment above EUR 3.5 billion, with the option of a new investment "similar in scale and ambition to Philips".

At first glance the subject looks obvious: where is the acquisition? Five months have passed and, at 31 August, Exor's press page shows no major new holding announced publicly since the March results.

That would be telling the story backwards. The very next day, before analysts, John Elkann explained that in uncertain times one should be prudent, patient and liquid. He added that timing would depend on the quality of the opportunity, and that all the major allocation options remained open.

In other words, Exor did not announce an appointment. It announced a capacity, then explained that the ability not to use it immediately had value in itself.

"More than EUR 3.5 billion" is not a pile of cash already in hand

This is the first point to clarify, and it changes the whole reading. At 31 December 2025, Exor did not hold EUR 3.5 billion of cash. It held EUR 1,408 million, against EUR 169 million a year earlier.

The slide shown to analysts builds the rest:

The release rounds that future capacity to "more than 3.5 billion". It is therefore a projected balance-sheet construction after the announced transactions, not a snapshot of a bank account on 23 March, still less on 31 August.

The consequence is direct. The largest expected source of cash, the Iveco disposal, is worth EUR 1.4 billion on its own and has not been received. Measuring Exor's inaction against an envelope that has not yet become liquid would be measuring the wrong quantity.

Philips gives a scale, not a date

Why is the Philips reference useful? Because it makes the intention quantifiable. In August 2023, Exor invested EUR 2,771 million to raise its Philips stake to 15.25%, an amount published in its 2023 annual report.

A future investment "similar in scale" therefore means something concrete: Exor considers itself able to sign, when the context justifies it, a new multi-billion cheque in a large company. It means neither exactly EUR 2,771 million, nor an obligation to repeat Philips, nor a timetable.

Four possible routes for the same euro

Perhaps the most instructive part of the 24 March call is this: Exor does not think only in terms of acquisitions. The allocator's craft is to compare uses against one another before giving up liquidity.

Those last two lines are enough to dismiss the idea of an idle holding company. In 2025 alone, between buybacks and the reinforcement of Philips and bioMérieux, Exor committed around EUR 1.8 billion. Capital is moving; it simply is not going where a hasty reading looks for it.

Leverage leaves room, it does not create a war chest

The balance sheet adds a second layer of safety, and one must resist reading it as an acquisition reserve.

It would be tempting to convert the gap between 6.9% and 15% mechanically into additional firepower. That would be too simple, and it would be wrong. Three published facts forbid it.

First, the relevant ratio is not 6.9% but 9.2% once outstanding commitments are included. Second, Exor lowered its leverage target from 20% to 15%, and wrote why: to strengthen its credit profile. A limit one has just deliberately tightened cannot be read as an envelope to be spent. Third, the company states its commitment to maintaining its A- rating from S&P, and separately holds EUR 1.1 billion of committed credit facilities, whose average tenor has been extended to four years.

Financial strength gives Exor more options. On its own, it says nothing about when an acquisition becomes attractive enough to be financed.

Lingotto is growing, but it is not the missing move

Lingotto's development might invite the reading of a strategic reorientation. The facts are more interesting once one resists that simplification.

The rise is 54.4% in a year, and appreciation explains close to eight tenths of it. The platform is growing because its strategies perform, not because Exor poured billions into it. The distinction is sharp between "the platform is growing" and "capital we decided to inject".

On 18 June, John Elkann took its chairmanship, Exor explaining that the platform's weight in the portfolio had grown with its performance. But on 24 March he had said Exor was then considering neither increasing nor reducing its allocation. Nothing therefore makes it an automatic substitute for the next large investment.

Patience has a value, and it has a cost

The case then becomes more interesting than a simple wait for an acquisition.

Holding several billion available provides an option. Exor can ride out unstable markets without depending on urgent financing, respond quickly if a large company becomes available at a price it finds attractive, and choose between buying, reinforcing and repurchasing its own shares.

But that optionality is not free. A euro held in cash does not earn what a euro placed in a value-creating business earns. And as long as Exor's shares trade well below net asset value, not repurchasing them is also giving up a possible use of capital.

That is precisely why speed is not the right indicator. The question is the return Exor will require before giving up the option to wait.

A capital allocator's craft is not to be always invested. It is to know when an opportunity is worth more than the liquidity given up to seize it.

What is actually worth watching

On 23 March, Exor gave the size of the next move it might make. On 24 March, it gave the rule: do not rush.

Five months on, the absence of a large acquisition is therefore neither a surprise nor, in itself, a sign of hesitation. The largest announced disposal has not been received, and available capital can go to four competing uses, two of which were heavily used in 2025.

The subject is not how long Exor can go without signing. It is which opportunity will be convincing enough for the holding company to give up part of that optionality. That is when the Philips reference becomes genuinely useful: not as a promise made in March, but as the yardstick for judging the next choice.

Three questions arise on 22 September, and none is a deadline.